Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity.

[1]  M. Hallek,et al.  Rituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells , 2004, Annals of Hematology.

[2]  P. Staib,et al.  Results of a phase II trial of a fludarabine with concomitant application of alemtuzumab in a four-weekly schedule (FluCam) in patients with relapsed CLL. 2nd Interim analysis. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  S. Schichman,et al.  Alemtuzumab (CAMPATH 1H) does not kill chronic lymphocytic leukemia cells in serum free medium. , 2004, Leukemia research.

[4]  Lisa L. Smith,et al.  Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. , 2004, Blood.

[5]  I. Pastan,et al.  Induction of caspase-dependent programmed cell death in B-cell chronic lymphocytic leukemia by anti-CD22 immunotoxins. , 2004, Blood.

[6]  T. Möröy,et al.  ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia , 2003, Leukemia.

[7]  M. Lishner,et al.  Simvastatin induces apoptosis of B-CLL cells by activation of mitochondrial caspase 9. , 2003, Experimental hematology.

[8]  E. Montserrat,et al.  Mechanism of action and resistance to monoclonal antibody therapy. , 2003, Seminars in oncology.

[9]  J. Byrd,et al.  Rituximab in B-cell chronic lymphocytic leukemia. , 2003, Seminars in oncology.

[10]  M. Minden,et al.  Bcl-2 and apoptosis in chronic lymphocytic leukemia , 2003, Current treatment options in oncology.

[11]  M. Andreeff,et al.  Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. , 2003, Blood.

[12]  R. Mercier,et al.  Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  A. López-Guillermo,et al.  Spontaneous and drug-induced apoptosis is mediated by conformational changes of Bax and Bak in B-cell chronic lymphocytic leukemia. , 2002, Blood.

[14]  L. Andritsos,et al.  Chronic lymphocytic leukemia , 2002, Current treatment options in oncology.

[15]  J. Byrd,et al.  Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. , 2002, Blood.

[16]  A. Rawstron,et al.  Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. , 2002, Blood.

[17]  J. Byrd,et al.  The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. , 2002, Blood.

[18]  H. Waldmann.  A personal history of the CAMPATH-1H antibody , 2002, Medical oncology.

[19]  J. Dürig,et al.  CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia , 2002, Leukemia.

[20]  K. Ganeshaguru,et al.  Caspase 8 activation independent of Fas (CD95/APO-1) signaling may mediate killing of B-chronic lymphocytic leukemia cells by cytotoxic drugs or gamma radiation. , 2001, Blood.

[21]  J. Dürig,et al.  Differential expression of chemokine receptors in B cell malignancies , 2001, Leukemia.

[22]  M. Grever,et al.  Novel therapies for chronic lymphocytic leukemia in the 21st century. , 2000, Seminars in oncology.

[23]  W. Rowan,et al.  Cross‐linking of the CAMPATH‐1 antigen (CD52) mediates growth inhibition in human B‐ and T‐lymphoma cell lines, and subsequent emergence of CD52‐deficient cells , 1998, Immunology.

[24]  M. Ormerod.  The study of apoptotic cells by flow cytometry , 1998, Leukemia.

[25]  John Calvin Reed.  Molecular biology of chronic lymphocytic leukemia. , 1998, Seminars in oncology.

[26]  M. Dyer,et al.  Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Z. Darżynkiewicz,et al.  Cytometry in cell necrobiology: analysis of apoptosis and accidental cell death (necrosis). , 1997, Cytometry.

[28]  E. Montserrat,et al.  Chronic lymphocytic leukemia. , 1995, The New England journal of medicine.

[29]  C. Reutelingsperger,et al.  Expression on B Cells Undergoing Apoptosis Annexin V for Flow Cytometric Detection of Phosphatidylserine , 2022 .

[30]  J. Greenwood,et al.  Structural motifs involved in human IgG antibody effector functions , 1993, European journal of immunology.

[31]  M Schena,et al.  Growth- and differentiation-associated expression of bcl-2 in B-chronic lymphocytic leukemia cells. , 1992, Blood.

[32]  H. Waldmann,et al.  IMPORTANCE OF ANTIGEN SPECIFICITY FOR COMPLEMENT‐MEDIATED LYSIS BY MONOCLONAL ANTIBODIES , 1988, European journal of immunology.

[33]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.